Best vet PV service providers ranked – what to look for before choosing a partner

Choosing an external pharmacovigilance partner is an important decision for any company responsible for veterinary medicinal products. Effective veterinary pharmacovigilance requires specialised expertise, reliable processes, and continuous oversight throughout the product lifecycle. The right provider can strengthen internal capabilities and support the consistent management of pharmacovigilance activities, while the wrong fit can create additional interfaces, unclear responsibilities, and unnecessary operational complexity.

This makes the search for a veterinary pharmacovigilance service provider about much more than comparing lists of available services.

Companies searching for best vet PV service providers ranked are often already at the stage of evaluating potential partners. Yet there is no universal ranking that can determine which provider is best for every organisation. The most suitable partner depends on the company’s product portfolio, markets, existing pharmacovigilance organisation, internal resources, and the scope of activities that require external support.

Why does choosing the right veterinary pharmacovigilance service provider matter?

Veterinary pharmacovigilance is an ongoing responsibility that extends throughout the lifecycle of an authorised veterinary medicinal product.

Within the EU, marketing authorisation holders must have a pharmacovigilance system in place for monitoring and ensuring the safety of their medicines on the European market. The applicable framework also requires an adequate and effective quality management system for pharmacovigilance activities.

External expertise can support companies in meeting these responsibilities, particularly where specialised knowledge or additional capacity is required. However, selecting a provider should not be approached as a simple transfer of operational tasks.

Importantly, outsourcing pharmacovigilance activities does not transfer the ultimate responsibility for pharmacovigilance away from the marketing authorisation holder. The MAH remains responsible for fulfilling its pharmacovigilance obligations and for the quality and integrity of its pharmacovigilance system, making appropriate provider selection and oversight essential.

The external partner needs to work effectively within the company’s wider pharmacovigilance framework. This means that veterinary expertise, quality processes, communication, capacity, governance, and regulatory knowledge can be just as important as the individual services listed in a commercial proposal.

For buyers, the question therefore becomes not simply “What can this provider do?” but “Can this provider deliver these activities reliably within our pharmacovigilance system?”

Best vet PV service providers ranked: what actually separates providers?

A ranking may provide a starting point for identifying potential suppliers, but it cannot show whether a provider is the right operational fit for a specific organisation.

When comparing potential partners, companies should look beyond company size, visibility, and the length of the service catalogue. Several factors can reveal much more about whether a provider is equipped to become a reliable part of the company’s pharmacovigilance organisation.

Veterinary-specific pharmacovigilance expertise

Veterinary pharmacovigilance has its own regulatory framework and scientific considerations. Companies should therefore determine whether the provider has genuine veterinary-specific expertise rather than relying primarily on experience from human pharmacovigilance.

The professionals supporting the account should understand the requirements applicable to veterinary medicinal products as well as the particular activities included within the proposed service model.

This becomes especially important when a company requires scientific input for activities such as veterinary signal detection, where pharmacovigilance data must be evaluated to identify potential new risks or changes in known risks associated with veterinary medicinal products.

Regulatory knowledge

For companies operating in the EU, potential providers should demonstrate an appropriate understanding of Regulation (EU) 2019/6 and applicable Veterinary Good Pharmacovigilance Practices.

The VGVP framework addresses several areas of veterinary pharmacovigilance, including pharmacovigilance systems and their quality management systems, signal management, collection and recording of suspected adverse events, communication, and pharmacovigilance inspections.

The relationship between QPPV and veterinary pharmacovigilance is particularly important when external support involves oversight of the pharmacovigilance system, as the QPPV plays a central role in ensuring that pharmacovigilance activities are appropriately managed and supervised.

Regulatory knowledge becomes particularly important when externally managed activities interact directly with the MAH’s wider pharmacovigilance system.

Scope of veterinary pharmacovigilance services

Not every company requires the same level of external support. One organisation may need expertise for a specific activity, while another may be looking for a provider capable of supporting several connected areas of its pharmacovigilance system.

Companies should therefore compare the required scope with the provider’s actual capabilities. They should also consider whether the provider could accommodate future requirements if the product portfolio, geographic coverage, or level of outsourcing expands.

A provider that meets an immediate requirement may not necessarily be the most appropriate long-term partner.

Quality framework and audit readiness

Quality should be evaluated in practice rather than through general statements about compliance.

Companies should understand how a potential provider controls procedures, manages training, monitors performance, handles deviations, maintains appropriate documentation, and prepares for audits.

This is particularly relevant because EMA expects MAHs to have the means to verify the quality of outsourced pharmacovigilance services, the provider’s capacity to perform assigned tasks, and the existence of appropriate quality assurance and quality control systems. Third parties carrying out pharmacovigilance activities must also accept audits by or on behalf of the MAH. The right of the MAH to audit the provider should also be clearly addressed in the contractual arrangement.

Capacity and service continuity

Expertise is valuable only when it is available when required. Companies should therefore understand how the provider manages workload fluctuations, staff availability, back-up arrangements, and business continuity.

This can be particularly important for time-sensitive pharmacovigilance activities. A provider should be able to explain what happens when a key team member becomes unavailable or when the client’s workload increases unexpectedly.

Evaluating these arrangements before appointment can provide a more realistic picture of how reliable the service will be once the partnership begins.

Communication and governance

Technical expertise alone does not guarantee a successful outsourcing relationship. Clear communication and governance can be equally important.

Before choosing a provider, companies should understand who will be responsible for routine communication, how responsibilities will be divided, how issues will be escalated, and how the external team will interact with internal pharmacovigilance, regulatory, quality, and other relevant functions.

A provider that can explain these processes clearly before contract signature is generally easier to evaluate than one that focuses only on the services it can technically perform.

Which services should you look for in a veterinary pharmacovigilance provider?

The required service scope depends heavily on the company’s existing pharmacovigilance organisation and internal capabilities. For companies considering veterinary pharmacovigilance outsourcing, the first step should be to determine which activities require external expertise and how that support will integrate with the existing pharmacovigilance system.

A veterinary pharmacovigilance service provider may support activities such as QPPV services and support, veterinary safety case management, signal management and detection, literature activities, pharmacovigilance system and PSMF support, training, quality activities, and preparation for audits or inspections.

This does not mean that companies should necessarily select the provider offering the longest possible list of services.

The more important question is whether the provider has the right capabilities for the activities the company actually needs to outsource and whether those activities can be effectively integrated into the existing pharmacovigilance system.

This is particularly relevant for major subcontracting arrangements. EMA specifically refers to areas such as the role of the QPPV, electronic reporting of adverse events, main databases, signal detection, and literature search when discussing pharmacovigilance activities subcontracted by an MAH.

What should companies ask before choosing a veterinary PV provider?

Commercial proposals can make different providers appear very similar. More detailed discussions with shortlisted suppliers can reveal important differences in how the service will actually operate.

Who will actually perform the work?

The people delivering the service can matter more than the overall size or visibility of the provider.

Companies should understand who will be assigned to the account, what experience these professionals have, and how veterinary-specific expertise will be made available when required.

This is also an opportunity to determine whether the experts presented during the commercial process are the same people who will remain involved after the contract has been signed.

Will any activities be subcontracted further?

Companies should understand whether the provider intends to perform all agreed activities internally or whether additional subcontractors will be involved.

This matters because every additional party can create another interface that needs to be appropriately managed. EMA guidance expects contractual arrangements to address subcontracting, and activities subcontracted further by a contract acceptor should be subject to the MAH’s approval.

Understanding the delivery model before appointment can therefore help avoid unexpected complexity later.

How will responsibilities be divided?

The scope of the agreement should make it clear where the provider’s responsibilities begin and end and which responsibilities remain within the company.

This should extend beyond broad descriptions such as “case management” or “signal management”. Both parties need a common understanding of the individual activities, relevant timelines, data transfers, communication pathways, and escalation processes involved.

How will quality and performance be monitored?

A prospective provider should be able to explain how it monitors its own performance and how the client will be able to maintain appropriate oversight.

This discussion may include performance indicators, quality controls, audits, documentation, issue management, and mechanisms for addressing deviations or changes.

The goal is to understand how quality will work once the relationship becomes operational rather than simply confirming that the provider has a quality system.

How will service continuity be maintained?

Companies should also ask what happens when circumstances change.

The provider should be able to explain how it manages staff absences, workload increases, changes in scope, urgent safety issues, and other situations that could affect service delivery.

For companies looking for a long-term veterinary pharmacovigilance service provider, this flexibility can become an important differentiator between potential partners.

Should price determine your choice of veterinary PV provider?

Price should be part of the provider-selection process, but it should not determine the decision in isolation. A lower commercial proposal may become less attractive if the service requires substantial internal coordination, provides limited access to veterinary specialists, depends heavily on additional subcontractors, or cannot easily accommodate changing requirements.

The same principle applies at the opposite end of the market. The largest or most visible provider is not automatically the best fit for every organisation.

Companies should instead consider the total value of the proposed partnership. This includes the expertise available, the quality framework, responsiveness, continuity, level of internal coordination required, and ability of the provider to support the company as its requirements evolve.

The most commercially attractive option may therefore be the provider that creates the most effective operating model rather than the one offering the lowest initial price.

What can a specialised veterinary pharmacovigilance provider offer?

Specialised providers such as Billev Pharma East can support companies looking for veterinary-specific expertise combined with broader pharmacovigilance, regulatory, and quality capabilities.

Billev Pharma East provides veterinary pharmacovigilance support through a multidisciplinary model combining veterinary, pharmacovigilance, regulatory, and quality expertise. This enables the scope of support to be adapted according to the capabilities already available within the client’s organisation and the activities for which additional expertise is required.

When comparing providers, the relevant question is therefore whether this type of multidisciplinary model matches the company’s product portfolio, internal resources, regulatory responsibilities, and expectations for an external veterinary pharmacovigilance service provider.

How should companies make the final provider decision?

Once a shortlist has been established, companies should move from comparing claims on paper to verifying how each provider would perform in practice.

Companies should also look beyond written proposals. Discussions with the proposed delivery team, qualification activities, references where available, contractual negotiations, and audits where appropriate can provide a clearer understanding of how the partnership would operate in practice.

Future requirements should form part of this assessment as well. A provider suitable for a single activity today may not necessarily be able to support a broader product portfolio or more extensive outsourcing model later.

Ultimately, the answer to best vet PV service providers ranked will differ between organisations. The right partner is the one whose veterinary expertise, quality framework, service capabilities, and operating model most closely match the company’s actual pharmacovigilance requirements.

Frequently asked questions

What is a veterinary pharmacovigilance service provider?

A veterinary pharmacovigilance service provider is an external specialist that supports pharmaceutical companies and marketing authorisation holders with veterinary pharmacovigilance expertise and activities. Support may range from individual specialist services to broader operational pharmacovigilance activities.

How do you compare veterinary pharmacovigilance service providers?

When comparing providers, companies should assess whether each veterinary pharmacovigilance service provider offers the right combination of veterinary expertise, regulatory knowledge, quality systems, service scope, capacity, continuity, communication, and governance for their specific requirements.

Can veterinary pharmacovigilance activities be outsourced?

Yes. Veterinary pharmacovigilance activities and functions can be outsourced to a veterinary pharmacovigilance service provider. However, under the EU framework, the marketing authorisation holder retains ultimate responsibility for its pharmacovigilance obligations and for the quality and integrity of its pharmacovigilance system.

Sources: 1 – European Medicines Agency (EMA). (2025). Veterinary pharmacovigilance inspections: Q&As. European Medicines Agency, 2 – European Medicines Agency (EMA). (2021). Guideline on veterinary good pharmacovigilance practices (VGVP) – Module: Pharmacovigilance systems, their quality management systems and pharmacovigilance system master files. European Medicines Agency, 3 – European Medicines Agency (EMA). (n.d.). Pharmacovigilance system (veterinary medicines). European Medicines Agency, 4 – European Commission. (2021). Commission Implementing Regulation (EU) 2021/1281 of 2 August 2021 laying down rules for the application of Regulation (EU) 2019/6 as regards good pharmacovigilance practice and the pharmacovigilance system master file for veterinary medicinal products. Official Journal of the European Union.